Skip to main content
. 2010 Dec 22;5(12):e15737. doi: 10.1371/journal.pone.0015737

Table 1. Patient and tumor characteristics stratified by nuclear RB1CC1 expression.

Feature Number Nuclear RB1CC1 p-Value
negative (%) positive (%)
Menopause 0.1204
Pre- 142 37 (37) 105 (47)
Post- 182 62 (62) 120 (53)
anti-Estrogen therapy 0.0540
none 85 33 (33) 52 (23)
performed 239 66 (67) 173 (77)
Chemotherapy <0.0001
none 179 33 (33) 146 (65)
performed 145 66 (67) 79 (35)
Radiation 0.1248
none 108 27 (27) 81 (36)
performed 216 72 (73) 144 (64)
T grade: tumor size 0.0805
≤T1 138 35 (35) 103 (46)
T2≤ 186 64 (65) 122 (54)
Nodes 0.0567
negative 210 56 (58) 154 (69)
positive 111 41 (43) 70 (31)
Stage: TNM class 0.2605
≤IIA 228 64 (67) 164 (73)
IIB≤ 93 32 (33) 61 (27)
ER 0.0689
positive 188 50 (51) 138 (61)
negative 136 49 (49) 87 (39)
PR 0.0003
positive 170 37 (37) 133 (59)
negative 154 62 (63) 92 (41)
HER2 0.1553
negative 290 85 (86) 205 (91)
positive 34 14 (14) 20 (9)
Triple Negative 0.0003
others 237 59 (60) 178 (79)
triple negative 87 40 (40) 47 (21)
p53 0.3200
normal 244 71 (72) 173 (77)
abnormal 80 28 (28) 52 (23)
RB1 0.0833
positive 308 91 (92) 217 (96)
negative 16 8 (8) 8 (4)
RB1CC1 ------
positive 225 0 (0) 225 (100)
negative 99 99 (100) 0 (0)
RB1CC1/RB1/p53 ------
normal 169 0 (0) 169 (75)
abnormal 155 99 (100) 56 (25)

Chi-square and Fisher's exact tests was used to evaluate the relationships between clinical parameters and nuclear RB1CC1 expression. p-value <0.05, statistically significant.